Related Experiment Video
Updated: Aug 15, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study
Annie Vallières1, Charles M Morin, Bernard Guay
1Ecole de psychologie, Université Laval, Pavillon FAS, Québec, Canada G1K 7P4. annie.vallieres@psy.ulaval.ca
Abstract:
This study explores the efficacy of sequential treatments involving medication and cognitive behavioral treatment (CBT) for primary insomnia. Seventeen participants took part in a multiple baseline design and were assigned to: (a) medication for 5 weeks, followed by combined medication plus CBT for 5 weeks; (b) combined treatment for 5 weeks, followed by CBT alone; or (c) CBT alone. Each treatment sequence produced significant sleep improvements, but at different points in time. For the first sequence, most of the sleep improvement was obtained after the introduction of CBT, while for the other sequence and CBT alone, improvement appeared during the first weeks. These results suggest that sleep improvement seems affected by the way treatments are combined. Also, a sequence beginning with a combined treatment followed by CBT alone seems to produce the best outcome. Additional research should be conducted with larger samples to determine the most effective sequence.
Related Concept Videos
Management of Insomnia
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Blind Procedures
CNS Depressants: Barbiturates and Benzodiazepines
Antidepressant Drugs: MAOIs and Other Agents